https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr
https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=07%2F21%2F2020&lupd_d=14&sort=nwst
STUDY TITLE:
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren’s Syndrome Phase Ib-IIa Placebo-Controlled Clinical Trial and Associated Mechanistic Studies
DESCRIPTION:
Condition: Sjogren’s Syndrome
Interventions: Drug: tofacitinib; Other: Placebo
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Not yet recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT04496960
FIRST POSTED:
Tue, 04 Aug 2020 12:00:00 EDT
LAST UPDATE POSTED:
08/04/20 07:19AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=07%2F21%2F2020&lupd_d=14&sort=nwst